CTLA4 and neoplasm: Moreover, treatment with the anti‐RANKL/PD‐1 BsAb achieved superior anti‐tumor control compared with the combination of anti‐RANKL plus anti‐PD‐1 in multiple s.c. tumor models and demonstrated equivalent anti‐tumor control to the currently most effective immunotherapy combination (anti‐PD‐1 plus anti‐CTLA‐4).